Most cardiac surgical procedures require an efficient and reliable cardiac arrest in order to provide a motionless and bloodless operating field, while simultaneously guaranteeing a maximized myocardial protection to preserve post-operative cardiac function. Several solutions have been developed yet several clinics continue to produce their own solution in-house. 
Cardioplexol (TM) is a new cardioplegic solution combining approved chemical compounds at non-toxic doses. Cardioplex, the initial solution developed at the Inselspital in Berne, Switzerland, has been used clinically for over 6 consecutive years, during which time it has shown to be safe and reliable. Compared to standard cardioplegic approaches available, it has shown several significant technical, surgical and clinical advantages and it is therefore the aim of the current proposal to make Cardioplexol (TM) available for the entire cardiac surgical community.
The purpose of the current study is to demonstrate the safety and efficiency of Cardioplexol (TM) when used as a cardioplegic solution during a cardiac surgical procedure.